upi.com
Cure8 news brief
Why This Matters
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce infections, operations, and long-term impact on the child and family.
Who Should Pay Attention
Parents/caregivers of children with Crohn's disease, pediatric gastroenterologists, clinicians managing newly diagnosed pediatric IBD, and families considering biologic therapy.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This report describes observational study findings that starting anti-TNF therapy soon after diagnosis was linked to fewer perianal complications. It does not provide detailed study methods, absolute risks, or follow-up duration in the news story, and it does not substitute for individualized medical advice.
If you care for a child with Crohn's, discuss risks, benefits, timing, and insurance/access issues for biologic therapy with your gastroenterology team.
Keep In Mind
This is a news summary of a study in Gut and reports large relative risk reductions but lacks full methodological details and absolute numbers. Observational findings need clinician interpretation before changing treatment. Cost and insurance access for anti-TNF drugs are practical considerations mentioned in the article.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationupi.com
Indexed viaBing News
Source typeResearch news
PublishedDec 27, 2024, 4:02 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Why anti-TNF drugs don't work for some kids with Crohn's disease - Medical Xpress
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.